MCID: BLR013
MIFTS: 52

Biliary Tract Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Biliary Tract Cancer

MalaCards integrated aliases for Biliary Tract Cancer:

Name: Biliary Tract Cancer 11 19 75 53 14 75
Malignant Tumour of Biliary Tract 11
Biliary Tract Neoplasms 43
Biliary Tract Neoplasm 16

Classifications:



External Ids:

Disease Ontology 11 DOID:4607
ICD9CM 34 156.9
MeSH 43 D001661
SNOMED-CT 68 126853008 93688006
ICD10 31 C24.9
UMLS 71 C0005426 C0750952

Summaries for Biliary Tract Cancer

Disease Ontology: 11 A hepatobiliary system cancer that results in malignant growth located in the gallbladder or located in the bile duct.

MalaCards based summary: Biliary Tract Cancer, also known as malignant tumour of biliary tract, is related to cholangiocarcinoma and gallbladder cancer. An important gene associated with Biliary Tract Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Signal Transduction and GPCR Pathway. The drugs Gemcitabine and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include gallbladder, bile duct and lymph node, and related phenotypes are Decreased viability with paclitaxel and Increased cell viability after pRB stimulation

Wikipedia: 75 Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.... more...

Related Diseases for Biliary Tract Cancer

Diseases related to Biliary Tract Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 422)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 32.8 SMAD4 PTGS2 MUC5AC MUC4 MTOR MIR21
2 gallbladder cancer 32.7 TGFBR2 SMAD4 MUC5AC MLH1 MIR17 MIR145
3 bile duct cancer 32.7 SMAD4 MUC5AC MUC4 MIR21 MIR17 MIR145
4 intrahepatic cholangiocarcinoma 32.1 MUC4 MIR17 ERBB2 EGFR
5 ampulla of vater cancer 31.8 SMAD4 MUC5AC MLH1 MIR145 ERBB2 EGFR
6 gallbladder disease 31.6 MIR17 MIR145 MIR143 IL6 ERBB2 EGFR
7 exanthem 31.6 MTOR IL6 ERBB2 EGFR
8 thrombocytopenia 31.5 SMAD4 RUNX3 MIR21 IL6 HDAC9 ERBB2
9 cholecystitis 31.3 MUC5AC MUC4 EGFR
10 biliary tract disease 31.3 MUC5AC MIR21 MIR17 MIR145 MIR143 IL6
11 breast ductal carcinoma 31.3 TGFBR2 SMAD4 MUC5AC MET ERBB2 EGFR
12 adenocarcinoma 31.2 TGFBR2 SMAD4 PTGS2 MUC5AC MUC4 MLH1
13 peripheral nervous system disease 31.1 PTGS2 MTOR MIR21 MIR17 MIR145 MIR143
14 pancreatic ductal adenocarcinoma 31.1 SMAD4 MIR21 MIR17 MIR145 MIR143
15 hepatocellular carcinoma 31.0 TGFBR2 SMAD4 RUNX3 PTGS2 MUC4 MTOR
16 bladder cancer 31.0 PTGS2 MTOR MLH1 MIR21 MIR17 MIR145
17 pancreatic cancer 31.0 TGFBR2 SMAD4 RUNX3 PTGS2 MUC5AC MUC4
18 pancreatic adenocarcinoma 31.0 TGFBR2 SMAD4 PTGS2 MUC4 MTOR MET
19 diabetes mellitus 30.8 PTGS2 MTOR MIR21 MIR17 MIR145 MIR143
20 lynch syndrome 30.8 TGFBR2 SMAD4 RUNX3 PTGS2 MLH1 MIR17
21 pancreatic ductal carcinoma 30.7 SMAD4 MUC5AC ERBB2 EGFR
22 stomatitis 30.7 MTOR IL6 DPYD
23 duodenum adenocarcinoma 30.7 SMAD4 MUC5AC MLH1
24 gastroesophageal adenocarcinoma 30.7 MET ERBB2 EGFR
25 ampulla of vater adenocarcinoma 30.7 SMAD4 MUC5AC MIR145
26 adenoma 30.7 TGFBR2 SMAD4 PTGS2 MUC5AC MLH1
27 peptic ulcer disease 30.6 PTGS2 MUC5AC IL6
28 gastric ulcer 30.6 PTGS2 MET IL6
29 inherited cancer-predisposing syndrome 30.6 SMAD4 MLH1 MET EGFR
30 bap1 tumor predisposition syndrome 30.6 SMAD4 MLH1 MET EGFR
31 hereditary breast ovarian cancer syndrome 30.6 SMAD4 MLH1 ERBB2 EGFR
32 gastric adenocarcinoma 30.6 SMAD4 PTGS2 MUC4 MTOR MLH1 MET
33 gastrointestinal stromal tumor 30.6 MTOR MET ERBB2 EGFR
34 bile duct disease 30.6 MIR21 MIR17 MIR145 MIR143 IL6
35 esophagitis 30.5 PTGS2 IL6 EGFR
36 respiratory failure 30.5 MUC5AC MIR21 MIR17 IL6
37 ovarian cancer 30.3 TGFBR2 SMAD4 PTGS2 MUC5AC MUC4 MTOR
38 breast cancer 30.2 TGFBR2 SMAD4 RUNX3 PTGS2 MTOR MLH1
39 gastric cancer 30.2 TGFBR2 SMAD4 RUNX3 PTGS2 MUC5AC MUC4
40 carcinoma of gallbladder and extrahepatic biliary tract 11.1
41 neutropenia 10.9
42 factor vii deficiency 10.8
43 gallbladder disease 1 10.7
44 cholangitis 10.6
45 klatskin's tumor 10.6
46 signet ring cell adenocarcinoma 10.5 MUC5AC MLH1 ERBB2
47 paronychia 10.5 MTOR ERBB2 EGFR
48 small intestine adenocarcinoma 10.5 SMAD4 MUC5AC MLH1
49 pancreatic signet ring cell adenocarcinoma 10.5 MUC5AC MUC4 MLH1
50 gastroesophageal junction adenocarcinoma 10.5 MET ERBB2 EGFR

Graphical network of the top 20 diseases related to Biliary Tract Cancer:



Diseases related to Biliary Tract Cancer

Symptoms & Phenotypes for Biliary Tract Cancer

GenomeRNAi Phenotypes related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 9.35 EGFR MTOR
2 Decreased viability with paclitaxel GR00179-A-2 9.35 MTOR
3 Decreased viability with paclitaxel GR00179-A-3 9.35 EGFR MTOR
4 Increased cell viability after pRB stimulation GR00230-A-1 8.92 EGFR ERBB2 MET TGFBR2

MGI Mouse Phenotypes related to Biliary Tract Cancer:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 EGFR ERBB2 IL6 LGR4 MET MIR143
2 growth/size/body region MP:0005378 10.3 EGFR ERBB2 HDAC9 IL6 LGR4 MET
3 muscle MP:0005369 10.26 EGFR ERBB2 HDAC9 IL6 MET MIR145
4 endocrine/exocrine gland MP:0005379 10.21 EGFR ERBB2 IL6 LGR4 MET MLH1
5 neoplasm MP:0002006 10.2 EGFR ERBB2 IL6 MET MLH1 MUC4
6 digestive/alimentary MP:0005381 10.18 DPYD EGFR ERBB2 IL6 LGR4 MET
7 renal/urinary system MP:0005367 10.14 EGFR IL6 LGR4 MET MTOR PTGS2
8 cardiovascular system MP:0005385 10.13 EGFR ERBB2 HDAC9 IL6 LGR4 MET
9 liver/biliary system MP:0005370 10.11 EGFR IL6 LGR4 MET MTAP PTGS2
10 immune system MP:0005387 10.07 EGFR IL6 LGR4 MET MLH1 MTAP
11 embryo MP:0005380 10.06 EGFR ERBB2 LGR4 MET MTAP MTOR
12 adipose tissue MP:0005375 10.04 EGFR IL6 LGR4 MTOR PTGS2 RUNX3
13 respiratory system MP:0005388 9.9 EGFR ERBB2 IL6 MET MLH1 MTAP
14 mortality/aging MP:0010768 9.83 EGFR ERBB2 HDAC9 IL6 LGR4 MET
15 integument MP:0010771 9.32 EGFR ERBB2 IL6 LGR4 MLH1 MTAP

Drugs & Therapeutics for Biliary Tract Cancer

Drugs for Biliary Tract Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
2
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
3
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 11947679 6857599
4
Magnesium sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9
5
Durvalumab Approved, Investigational Phase 3 1428935-60-7
6
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
7
Trastuzumab Approved, Investigational Phase 3 180288-69-1
8
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
9
Niraparib Approved, Investigational Phase 3 1038915-60-4 24958200
10
Futibatinib Approved, Investigational Phase 3 1448169-71-8 71621331
11
Ivosidenib Approved, Investigational Phase 3 1448347-49-6 78140854 71657455
12
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
13
Fluorouracil Approved Phase 3 51-21-8 3385
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
15
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
16 Antiemetics Phase 3
17 Emetics Phase 3
18 Antiviral Agents Phase 3
19 Anti-Infective Agents Phase 3
20 Mitogens Phase 2, Phase 3
21 Antineoplastic Agents, Immunological Phase 3
22 Albumin-Bound Paclitaxel Phase 2, Phase 3
23 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
24 Antimetabolites Phase 3
25 Immunosuppressive Agents Phase 3
26 Immunologic Factors Phase 3
27 Vitamins Phase 3
28 Folate Phase 3
29 Vitamin B9 Phase 3
30 Trace Elements Phase 3
31 Vitamin B Complex Phase 3
32 Antidotes Phase 3
33 Micronutrients Phase 3
34 Protective Agents Phase 3
35
Racepinephrine Approved, Vet_approved Phase 2 51-43-4, 329-65-7 838 5816
36
Ropivacaine Approved Phase 2 84057-95-4 71273 175805
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2 437-38-7 3345
38
Oxycodone Approved, Illicit, Investigational Phase 2 76-42-6 5284603
39
Morphine Approved, Investigational Phase 2 57-27-2 5288826
40
Cetuximab Approved Phase 2 205923-56-4
41
Mitomycin Approved Phase 2 50-07-7 5746
42
Panitumumab Approved, Investigational Phase 2 339177-26-3
43
Sargramostim Approved, Investigational Phase 2 123774-72-1
44
Olaparib Approved Phase 2 763113-22-0 23725625
45
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
46
Adenosine Approved, Investigational Phase 2 58-61-7 60961
47
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
48
Aldesleukin Approved Phase 2 110942-02-4
49
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
50
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230

Interventional clinical trials:

(show top 50) (show all 297)
# Name Status NCT ID Phase Drugs
1 The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer Unknown status NCT02943031 Phase 4
2 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
3 Re-intervention for Occluded Biliary Metal Stent in Malignant Distal Bile Duct Obstruction: a Prospective Randomized Multi-center Trial Comparing Covered and Uncovered Metal Stent Completed NCT01315522 Phase 4
4 Endoscopic Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
5 A Randomized, Open, Multi-center Phase IIb/III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Capecitabine in Advanced or Metastatic Biliary Tract Carcinoma (BTC) Patients Unknown status NCT03873532 Phase 2, Phase 3 Surufatinib;Capecitabine
6 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy Completed NCT03093870 Phase 2, Phase 3 Varlitinib;Capecitabine;Placebo (for Varlitinib)
7 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
8 Randomized Phase III Trial Comparing Gemcitabine/Cisplatin/S-1 With Gemcitabine/Cisplatin for Unresectable Biliary Tract Cancer Completed NCT02182778 Phase 3 Gemcitabine/Cisplatin;Gemcitabine/Cisplatin /S-1
9 A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. Completed NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
10 Evaluation of Effects of Early Palliative Care on Quality of Life of Advanced Cancer Patients. A Multicenter Controlled Randomised Clinical Trial Completed NCT02988635 Phase 3
11 Randomised Phase II Trial of Cediranib (AZD2171) Versus Placebo in Addition to Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers Completed NCT00939848 Phase 2, Phase 3 gemcitabine;cisplatin;Placebo;cediranib
12 A Prospective Randomized Clinical Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy: Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy Completed NCT01731821 Phase 3
13 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
14 A Randomized, Multi-center Phase III Trial of Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine Alone in Curatively Resected Biliary Tract Cancer Recruiting NCT04401709 Phase 3 Gemcitabine/Capecitabine;Capecitabine
15 Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study Recruiting NCT03478488 Phase 3 KN035 plus Gemcitabine & oxaliplatin;Gemcitabine & oxaliplatin
16 Randomized, Placebo-controlled, Open-label, Phase 2b Clinical Trial to Evaluate the Antitumor Activity of Combination Therapy of SMT-NK and Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer Recruiting NCT05429697 Phase 2, Phase 3 SMT-NK inj.+Pembrolizumab;Pembrolizumab
17 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (ICC/ECC) - A Phase III Study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR) - The AIO/ CALGP/ ACO- GAIN-Trial - Recruiting NCT03673072 Phase 3 Gemcitabine;Cisplatin;Adjuvant chemotherapy
18 A Randomized, Open-label, Parallel Controlled, Multi-center Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Chemotherapy as Second-line Treatment in Subjects With Advanced Biliary Cancer Recruiting NCT04809142 Phase 3 TQB2450 Injection;Anlotinib hydrochloride;Oxaliplatin injection;Capecitabine tablets;Gemcitabine hydrochloride injection
19 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer Active, not recruiting NCT04066491 Phase 2, Phase 3 M7824;Placebo;Gemcitabine;Cisplatin
20 A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers Active, not recruiting NCT03875235 Phase 3 Durvalumab;Placebo
21 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Active, not recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
22 Open-Label, Multicenter, Phase II/III Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer After Gemcitabine and Cisplatin-Based Treatment Failure Not yet recruiting NCT05065957 Phase 2, Phase 3 D07001-softgel capsules + Xeloda (or TS-1);mFOLFOX
23 An Open, Single-arm Prospective Clinical Study Evaluating the Efficacy of Systemic Venous Gemcitabine-based Chemotherapy Combined With Immunocheckpoint Inhibitors in First-line Treatment of Advanced Biliary Malignancies Not yet recruiting NCT05487443 Phase 2, Phase 3 Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors
24 A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen Not yet recruiting NCT05506943 Phase 2, Phase 3 CTX-009;Paclitaxel
25 Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial Not yet recruiting NCT05615818 Phase 3 Futibatinib;Ivosidenib;Zanidatamab;Trastuzumab;Neratinib;Encorafenib;Binimetinib;Niraparib;Cisplatin;Gemcitabine
26 A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer Terminated NCT04163900 Phase 3 NUC-1031;Gemcitabine;Cisplatin
27 A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery Terminated NCT00090025 Phase 3 becatecarin;5-Fluorouracil Plus Leucovorin
28 A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 in Subjects With Cancer Withdrawn NCT02597465 Phase 3 SPARC1507;Reference1507
29 GAMBIT Trial: A Randomized,Non-comparative, Open-label Clinical Trial Evaluating Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer Unknown status NCT01859728 Phase 2 Irinotecan;Cisplatin;Gemcitabine
30 An Exploratory Study to Evaluate Efficacy and Safety of Fruquintinib as Second-line Treatment for Patients With Advanced or Metastatic Biliary Tract Cancer Unknown status NCT04156958 Phase 2 Fruquintinib
31 A Multicentre, Open-label Phase II Study of Nab-paclitaxel in Combination With Gemcitabine + Cisplatin as First Line Treatment in Patients With Unresectable Biliary Tract Cancer Unknown status NCT02632305 Phase 2 nab-paclitaxel in combination with gemcitabine + cisplatin
32 Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer: A Randomized, Controlled, Multicenter Phase II Clinical Trial Unknown status NCT04300959 Phase 2 Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin;Gemcitabine Plus(+)Cisplatin
33 A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer Unknown status NCT04692051 Phase 2 Nab-paclitaxel + Cisplatin;Gemcitabine + Cisplatin
34 Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer Unknown status NCT03144856 Phase 2 Apatinib
35 A Phase I/II, Open-label, Single-center Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Local Advanced/Metastatic Biliary Tract Cancer Unknown status NCT04004234 Phase 1, Phase 2 Manganese Chloride;nab-paclitaxel;Gemcitabine;anti-PD-1 antibody
36 Phase II Study of S-1 in Combination With Oxaliplatin and Irinotecan in Patients With Advanced, Recurrent or Metastatic Biliary Tract Cancer Unknown status NCT02527824 Phase 2 Oxaliplatin, Irinotecan, S-1
37 Toripalimab Combined With S1 and Albumin Paclitaxel as First Line in Patients With Advanced Biliary Tract Cancer: a Single-arm,One Center, Phase II Clinical Study Unknown status NCT04027764 Phase 2 Toripalimab Combined With S1 and Albumin Paclitaxel
38 Phase II Randomized Trial of S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) vs Gemcitabine and Cisplatin (GC) in Locally Advanced or Metastatic Biliary Tract Cancer Unknown status NCT03406299 Phase 2 Tegafur;Leucovorin;Oxaliplatin;Gemcitabine;Cisplatin
39 A Multicenter, Phase I-II Trial of Gemcitabine Plus Oxaliplatin and Nab-paclitaxel in Subjects With Advanced (Unresectable or Metastatic) Biliary Tract Cancer Unknown status NCT03943043 Phase 1, Phase 2 nab-paclitaxel
40 Multicenter Phase II Study of Docetaxel and Oxaliplatin Combination in Patients With Locally Advanced or Metastatic Biliary Tract Cancer Unknown status NCT01234051 Phase 2 Docetaxel, Oxaliplatin
41 An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma Unknown status NCT01180153 Phase 2 S-1 oxaliplatin
42 Multicenter Phase II Study of Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) in Patients With Locally Advanced or Metastatic Biliary Tract Cancer Unknown status NCT01494363 Phase 2 Fluorouracil;Leucovorin;Oxaliplatin;Irinotecan
43 A Pilot Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Patients With Advanced Unresectable or Metastatic Biliary Tract Cancers Unknown status NCT03311789 Phase 1, Phase 2 PD-1 inhibitor + Gemcitabine + Cisplatin
44 Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers: a Single-arm, Non-randomized, Single-center Clinical Trial and Biomarker Study Unknown status NCT04211168 Phase 2 Toripalimab plus Lenvatinib
45 A Phase 2 Study of Pyrotinib in Patients With Advanced/ Metastatic HER2-Altered Biliary Tract Cancers Who Have Failed One or Two Prior Lines of Therapies Unknown status NCT04571710 Phase 2 SHR1258
46 Multicenter, Phase II Study of Chemotherapy in Combination With Trastuzumab in Patients of Pretreated, HER2 Positive, Relapse or Metastatic Carcinoma of Digestive System Unknown status NCT03185988 Phase 2 chemotherapy in combination with trastuzumab for arm1;chemotherapy in combination with trastuzumab for arm2;chemotherapy in combination with trastuzumab for arm3;chemotherapy in combination with trastuzumab for arm4
47 Phase II Study of Second Line Capecitabine Plus Oxaliplatin (XELOX) in Patients With Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy Unknown status NCT02350686 Phase 2 capecitabine;oxaliplatin
48 Phase II Exploratory Study of S-1 Combined With Oxaliplatin Sequential S-1 Single-agent First-line Treatment of Unresectable Metastatic or Locally Advanced Biliary System, Periampullary Cancer and Pancreatic Cancer Unknown status NCT01811277 Phase 2 SOX sequential S-1
49 A Multicenter Phase II Trial of Preoperative Chemotherapy With Gemcitabine/ Cisplatin /S-1 (GCS) for Biliary Tract Cancers With Lymph Node Metastasis Diagnosed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Unknown status NCT01821248 Phase 2 Gemcitabine, Cisplatin, S-1
50 Comparison of Analgesic Efficacy After Major Surgery in Pancreatobiliary Cancers: Intravenous Patient-controlled Analgesia Versus Patient-controlled Epidural Analgesia Unknown status NCT04352023 Phase 2

Search NIH Clinical Center for Biliary Tract Cancer

Cochrane evidence based reviews: biliary tract neoplasms

Genetic Tests for Biliary Tract Cancer

Anatomical Context for Biliary Tract Cancer

Organs/tissues related to Biliary Tract Cancer:

FMA: Gallbladder, Bile Duct
MalaCards : Lymph Node, Skin, Liver, Pancreas, T Cells, Lung, Breast

Publications for Biliary Tract Cancer

Articles related to Biliary Tract Cancer:

(show top 50) (show all 1780)
# Title Authors PMID Year
1
EGFR and HER2 expression in advanced biliary tract cancer. 53 62
19777609 2009
2
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. 53 62
19509244 2009
3
Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers. 53 62
19571608 2009
4
MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. 53 62
18475301 2008
5
[Expressions and clinical significances of c-met, c-erbB-2, COX-2, and IL-6 in the biliary tract cancers]. 53 62
18159174 2007
6
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers. 53 62
17364234 2007
7
Restoration of RUNX3 enhances transforming growth factor-beta-dependent p21 expression in a biliary tract cancer cell line. 53 62
17470130 2007
8
CPT-11 (SN-38) chemotherapy may be selectively applicable to biliary tract cancer with low hMLH1 expression. 53 62
17465213 2007
9
Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment. 53 62
16820886 2006
10
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. 53 62
16926628 2006
11
K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. 53 62
12374683 2002
12
Allelotype analysis of the PTEN, Smad4 and DCC genes in biliary tract cancer. 53 62
12168833 2002
13
Infrequent microsatellite instability in biliary tract cancer. 53 62
11223838 2001
14
Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. 53 62
7645925 1995
15
Serum levels of c-erbB-2 protein in digestive diseases. 53 62
7528080 1994
16
A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer. 62
36459291 2022
17
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. 62
36400106 2022
18
Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature review. 62
35988887 2022
19
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. 62
36089135 2022
20
Blood-based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer. 62
36455598 2022
21
Natural Language Processing for Automated Classification of Qualitative Data From Interviews of Patients With Cancer. 62
35840523 2022
22
A rapid and sensitive ultra-performance liquid chromatography tandem mass spectrometry method for determination of anlotinib in plasma and dried blood spots: Method development, validation, and clinical application. 62
35918299 2022
23
Determination of temporal reproducibility and variability of cancer biomarkers in serum and EDTA plasma samples using a proximity extension assay. 62
36376783 2022
24
Phosphoproteomics revealed cellular signals immediately responding to disruption of cancer amino acid homeostasis induced by inhibition of L-type amino acid transporter 1. 62
36357940 2022
25
Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers. 62
36320173 2022
26
Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial. 62
36444498 2022
27
Cancer risk according to alcohol consumption trajectories: A population-based cohort study on 2.8 million Korean men. 62
36436924 2022
28
Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer. 62
36008616 2022
29
Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer? 62
35786978 2022
30
Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer. 62
36252287 2022
31
Preoperative controlling nutritional status score predicts systemic disease recurrence in patients with resectable biliary tract cancer. 62
36404251 2022
32
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. 62
36372281 2022
33
Average treatment effect of facility hepatopancreatobiliary malignancy case volume on survival of patients with nonoperatively managed hepatobiliary malignancies. 62
36402613 2022
34
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions. 62
36428670 2022
35
Curative surgical resection for initially unresectable metastatic gallbladder cancer following neoadjuvant chemotherapy: Case report and review of literature. 62
36242892 2022
36
Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer. 62
36102999 2022
37
Light-to-Moderate Alcohol Consumption Increases the Risk of Biliary Tract Cancer in Prediabetes and Diabetes, but Not in Normoglycemic Status: A Nationwide Cohort Study. 62
35696635 2022
38
Novel parameter for cancer chemosensitivity to fibroblast growth factor receptor inhibitors. 62
35950366 2022
39
Abdominal aortic calcification volume (AACV) is a predictive factor for postoperative complications associated with biliary tract cancer. 62
36447077 2022
40
Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015. 62
36384474 2022
41
Advances in Targeted Immunotherapy for Hepatobiliary Cancers. 62
36430440 2022
42
Age trends in biliary tract cancer incidence by anatomical subtype: A Swedish cohort study. 62
36174301 2022
43
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer. 62
35869145 2022
44
Associations between cigarette smoking and biliary tract cancer by anatomic subsite and sex: a prospective cohort study in Japan. 62
36030296 2022
45
Characteristic submucosal alteration in biliary carcinogenesis of pancreaticobiliary maljunction with a focus on inflammasome activation. 62
36259178 2022
46
Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors. 62
36305543 2022
47
A case of metachronous intraductal tubulopapillary carcinoma of the pancreas after surgery for gallbladder cancer-accompanied pancreaticobiliary maljunction. 62
35900671 2022
48
Micro-lymph node metastasis in intrahepatic cholangiocarcinoma showing pathological complete response to primary tumor and intrahepatic metastasis treated by gemcitabine plus cisplatin chemotherapy and radical surgery. 62
36239900 2022
49
Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer. 62
36257294 2022
50
Gallstones and risk of cancers of the liver, biliary tract and pancreas: a prospective study within two U.S. cohorts. 62
35715632 2022

Variations for Biliary Tract Cancer

Expression for Biliary Tract Cancer

Search GEO for disease gene expression data for Biliary Tract Cancer.

Pathways for Biliary Tract Cancer

Pathways related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1 13.67 TGFBR2 SMAD4 RUNX3 MTOR MET LGR4
2
Show member pathways
13.63 TGFBR2 SMAD4 PTGS2 MET IL6 HDAC9
3
Show member pathways
13.63 TGFBR2 SMAD4 MUC5AC MUC4 MTOR MLH1
4
Show member pathways
13.55 SMAD4 PTGS2 MTOR MET IL6 HDAC9
5
Show member pathways
13.25 TGFBR2 SMAD4 MTOR MET IL6 HDAC9
6
Show member pathways
12.75 TGFBR2 MTOR IL6 HDAC9 ERBB2 EGFR
7
Show member pathways
12.42 TGFBR2 SMAD4 PTGS2 MTOR MLH1 ERBB2
8
Show member pathways
12.37 SMAD4 MTOR ERBB2 EGFR
9
Show member pathways
12.31 EGFR ERBB2 MET MTOR TGFBR2
10
Show member pathways
12.29 MTOR MET IL6 ERBB2 EGFR
11
Show member pathways
12.15 MTOR MET ERBB2 EGFR
12 12.05 TGFBR2 SMAD4 MTOR EGFR
13
Show member pathways
11.93 TGFBR2 MTOR IL6 ERBB2 EGFR
14 11.86 MTOR MET LGR4 ERBB2 EGFR
15 11.81 MTOR MLH1 MIR145
16
Show member pathways
11.8 TGFBR2 SMAD4 IL6
17
Show member pathways
11.78 TGFBR2 SMAD4 IL6
18
Show member pathways
11.78 MTOR MET EGFR
19 11.76 TGFBR2 SMAD4 RUNX3 MTOR
20 11.71 SMAD4 MTOR IL6
21
Show member pathways
11.69 MIR17 MIR145 MIR143
22 11.65 TGFBR2 SMAD4 PTGS2 MLH1 IL6 EGFR
23 11.64 TGFBR2 SMAD4 ERBB2
24 11.57 MIR21 MIR145 IL6
25 11.56 MIR143 MIR145 MIR17 MIR21
26 11.51 SMAD4 PTGS2 IL6
27
Show member pathways
11.5 TGFBR2 SMAD4 ERBB2 EGFR
28 11.49 SMAD4 RUNX3 EGFR
29 11.43 TGFBR2 SMAD4 MET EGFR
30 11.42 SMAD4 MIR145 MIR143
31 11.42 TGFBR2 SMAD4 MTOR ERBB2 EGFR
32 11.29 EGFR ERBB2 MET
33 10.62 EGFR PTGS2
34 10.47 SMAD4 MTOR MET ERBB2 EGFR

GO Terms for Biliary Tract Cancer

Cellular components related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basal plasma membrane GO:0009925 9.1 MET ERBB2 EGFR

Biological processes related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.29 TGFBR2 PTGS2 MIR21 IL6 ERBB2 EGFR
2 negative regulation of apoptotic process GO:0043066 10.24 PTGS2 MTOR MIR21 IL6 ERBB2 EGFR
3 positive regulation of protein kinase B signaling GO:0051897 9.99 MIR21 MIR143 MET EGFR
4 embryo implantation GO:0007566 9.96 TGFBR2 PTGS2 MIR21
5 regulation of ERK1 and ERK2 cascade GO:0070372 9.85 MIR145 ERBB2 EGFR
6 activation of protein kinase B activity GO:0032148 9.78 MTOR MIR21 MIR143
7 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.74 IL6 MIR21
8 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.73 MIR21 MIR17 IL6
9 regulation of cell population proliferation GO:0042127 9.73 EGFR ERBB2 PTGS2 SMAD4 TGFBR2
10 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.67 MET MIR21
11 positive regulation of miRNA maturation GO:1903800 9.58 IL6 EGFR
12 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.55 MIR21 MIR17
13 aorta smooth muscle tissue morphogenesis GO:0060414 9.54 MIR145 MIR143
14 positive regulation of metalloendopeptidase activity GO:1904685 9.52 MIR21 MIR17
15 negative regulation of cardiac muscle hypertrophy GO:0010614 9.46 SMAD4 MIR21 MIR145
16 regulation of phenotypic switching GO:1900239 9.4 MIR145 MIR143
17 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.37 MIR17 MIR143
18 positive regulation of cellular response to hypoxia GO:1900039 9.32 MIR21 MIR145
19 positive regulation of epithelial to mesenchymal transition GO:0010718 9.28 TGFBR2 SMAD4 MTOR MIR21 IL6
20 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 8.96 MIR145 MIR143

Molecular functions related to Biliary Tract Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 8.92 MIR21 MIR17 MIR145 MIR143

Sources for Biliary Tract Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....